Short Interest for Most Consumer Staple Industries Fell in October
Always Celebrates a New Era of Zero Feel, Zero Leaks Period Protection With Their Biggest Stunt at Westfield London, as 86% of UK Women Admit to Taking Significant Steps to Avoid Period Mishaps Such as Leaks and Pad Discomfort Each Month
Ray Dalio's Strategic Moves in Q3 2024: A Deep Dive Into Procter & Gamble's Significant ...
Dr. Cameka Smith, Female Founder and CEO of The Boss Network, to Serve as a Presenter During The 2024 HBCU Honors, Presented by Procter & Gamble, Taking Place During Smith's Milestone 15th Anniversary Yearlong Celebration
Dow Rallies 281 Points On Gains For Procter & Gamble, Travelers Shares
FDA recommends stopping the use of common decongestants in cold medicines, glaxosmithkline (GSK.US) and other companies may be affected.
The Food and Drug Administration (FDA) announced on Thursday that it has proposed to remove the oral phenylephrine commonly used in cold and cough syrups from the active ingredients of over-the-counter nasal decongestants and deemed it ineffective.